Medication Administration

Medication Administration Public Act:

Medication Administration Public Act 103-0890

Summary of Changes 12/19/2024:

This legislation will make changes to the current Medication Administration Rule 116 in the following ways:

  1. As a result of this legislation, DDD is excited to announce that the competency-based training and assessment (CBTA) process for Rule 116 will be streamlined. There is a change in how to complete the initial CBTA for an authorized direct support professional (ADSP) as well as subsequent CBTAs for new individuals served and medication changes. Once an ADSP is authorized, subsequent CBTAs for new individuals served, or new medications, will no longer be automatically required. An information bulletin will be released in the new year.
  2. It allows insulin pumps to be used within the CILA setting and changes.
    1. Individuals will be required to be independent with their insulin pump.
    2. Providers will be required to have policies and procedures for assessing for independence with insulin pumps in place prior to the use of an insulin pump. Information bulletin to follow.
  3. Non-insulin injectable treatments (via pre-filled pen or auto-injectors) used for metabolic glycemic disorders (GLP-1 receptor agonists) will be allowed to be given by ADSPs after training. Information bulletin to follow in the new year.

UPDATES 2/26/25:

MEDICATION ADMINISTRATION CHANGES

As discussed in prior communication, legislative changes were passed that impacts Rule 116. Legislation can be read here: Illinois General Assembly - Full Text of Public Act 103-0890. Effective immediately, non-insulin injectable treatments via pre-filled pens and auto-injectors use to treat diabetes and obesity are allowed in settings governed by Rule 116. Additionally, there have been changes to the required training of authorized direct support professionals (ADSP). Associated forms and trainings are in development; for access to these, please email DHS.ClinicalServices@illinois.gov with questions.

Interim guidance: Draft Information Bulletins (see below) have been posted to provide interim guidance until Rule 116 can be updated to integrate the legislative changes.

The following Draft Information Bulletins are available for comment:

The following Final Information Bulletin has been posted:

Return to

DDD Home Page

Return to Bureau of Clinical Services Home Page